23 September 2020
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...